Sol-Gel Technologies Ltd.
SLGL
Rank in Stocks
#16603
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical... Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Share Price
$61.74
Last synced: 2026-11-09
Market Cap
$202.14M
Change (1 day)
1.20%
Change (1 year)
93.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sol-Gel Technologies Ltd. (SLGL)
Category
Healthcare
EPS for Sol-Gel Technologies Ltd. (SLGL)
EPS as of June 2026 TTM: $-5.64
According to Sol-Gel Technologies Ltd.'s latest financial reports, its current EPS (TTM) is $-5.64. At the end of 2025 the company had an EPS of $-2.20, an increase over its 2024 EPS of $-3.79.
EPS history for Sol-Gel Technologies Ltd. from 2014 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.64 | 156.36% |
| 2025 | $-2.20 | -41.95% |
| 2024 | $-3.79 | -62.14% |
| 2023 | $-10.01 | 1,440.00% |
| 2022 | $-0.65 | -146.43% |
| 2021 | $1.40 | -207.69% |
| 2020 | $-1.30 | 3.17% |
| 2019 | $-1.26 | -30.00% |
| 2018 | $-1.80 | 2.27% |
| 2017 | $-1.76 | -0.56% |
| 2016 | $-1.77 | 115.85% |
| 2015 | $-0.82 | -54.70% |
| 2014 | $-1.81 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -377.66% |
US
|
|
| $-7.07 | 25.35% |
US
|
|
| $-5.29 | -6.21% |
AU
|
|
| $12.88 | -328.37% |
BE
|
|
| $21.56 | -482.27% |
NL
|
Questions about Sol-Gel Technologies Ltd.'s earnings per share (EPS)
What is Sol-Gel Technologies Ltd.'s earnings per share (EPS)?
Sol-Gel Technologies Ltd.'s earnings per share (EPS) over the last twelve months is $-5.64, as of Jun 2026.
What was Sol-Gel Technologies Ltd.'s earnings per share (EPS) in 2025?
In 2025, Sol-Gel Technologies Ltd.'s earnings per share (EPS) was $-2.20, compared with $-3.79 in 2024.
How has Sol-Gel Technologies Ltd.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Sol-Gel Technologies Ltd.'s earnings per share (EPS) was highest in 2021 ($1.40) and lowest in 2023 ($-10.01).
How does Sol-Gel Technologies Ltd.'s earnings per share (EPS) compare with similar companies?
Sol-Gel Technologies Ltd.'s earnings per share (EPS) ($-5.64) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.